Table of Contents
The Federal Trade Commission reached a CVS Caremark insulin settlement that requires the pharmacy benefit manager to change its business practices as part of the agency’s antitrust case alleging the PBM inflated insulin list prices through rebate practices.
How Much the CVS Caremark Insulin Settlement Could Save Consumers
The FTC said the settlement will secure up to $8.5 billion in consumer savings over the next 10 years and unlock up to $4.5 billion in additional patient savings through point-of-sale rebates over the same period, according to a July 14 FTC news release. Combined, these projections suggest the CVS Caremark insulin settlement could generate meaningful financial relief for patients relying on insulin and other medications managed through the PBM.
What CVS Caremark Must Change Under the Settlement
Under the settlement, CVS Caremark must pass rebates through to patients at the point of sale, delink manufacturer fees from drug list prices, increase transparency for health plans, and give plan sponsors options to move away from rebate guarantees and spread pricing. The agreement also prohibits Caremark from interfering with pharmacies that work with hub service providers intended to improve medication access and affordability.
The Case Behind the CVS Caremark Insulin Settlement
The case dates back to September 2024, when the FTC sued Caremark, Express Scripts and Optum Rx, accusing the three PBMs of excluding low-cost insulins from formularies to secure higher rebates. This original lawsuit set the stage for the CVS Caremark insulin settlement now reached with one of the three named PBMs.
A Case That Stalled Before Resuming
The PBMs pushed back, and litigation stalled in April 2025 when the case was paused due to a lack of participating commissioners, before FTC Chair Andrew Ferguson ended his recusal and cleared the way for proceedings to resume. That procedural delay meant the case took nearly two years to reach this settlement stage.
How the CVS Caremark Insulin Settlement Compares to Express Scripts
The FTC reached a similar settlement with Express Scripts in February, requiring the PBM to pass through rebates at the point of sale, allow plan sponsors to move away from rebate guarantees, and pay community pharmacies based on drugs’ actual costs, while offering access to TrumpRx. The structural similarities between the Express Scripts deal and the CVS Caremark insulin settlement suggest the FTC is pursuing a consistent regulatory template across the PBM industry rather than negotiating fundamentally different terms with each company.
Where the Optum Rx Case Stands
The FTC’s case against Optum has been withdrawn from adjudication as the agency considers a consent agreement, suggesting a third settlement, potentially mirroring the CVS Caremark and Express Scripts deals, could still be forthcoming.
What This Means for PBM Industry Practices
With two of the three largest PBMs now under settlement terms requiring point-of-sale rebate pass-through and greater pricing transparency, the CVS Caremark insulin settlement signals a broader shift in how the FTC intends to regulate rebate-driven formulary practices across the pharmacy benefit management industry. If Optum Rx follows with a similar agreement, all three of the nation’s largest PBMs would be operating under comparable transparency and rebate-passthrough requirements.
What to Watch Going Forward
As CVS Caremark begins implementing the required changes, health plans, pharmacies, and patients will likely watch closely for how quickly point-of-sale rebate savings materialize in practice, given that the FTC’s own projections span a full decade. The outcome of the pending Optum Rx consent agreement negotiations will also be an important indicator of whether this CVS Caremark insulin settlement framework becomes the industry standard across all major PBMs.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
